Press releases
- Alkermes to Report Second Quarter Financial Results on July 24, 2024
- Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024
- Alkermes to Participate in Two Upcoming Investor Conferences
- Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
- Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
- Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
- Alkermes plc Reports First Quarter 2024 Financial Results
More ▼
Key statistics
As of last trade Alkermes Plc (8AK:STU) traded at 22.40, 6.67% above its 52-week low of 21.00, set on Nov 28, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 22.60 |
---|---|
High | 22.80 |
Low | 22.40 |
Bid | 22.60 |
Offer | 22.80 |
Previous close | 22.60 |
Average volume | 0.00 |
---|---|
Shares outstanding | 169.22m |
Free float | 167.09m |
P/E (TTM) | 7.03 |
Market cap | 4.16bn USD |
EPS (TTM) | 3.50 USD |
Data delayed at least 15 minutes, as of Jul 22 2024.
More ▼